Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Compensates Family Of Child In Fatal Flu Vaccination

This article was originally published in PharmAsia News

Executive Summary

Local authorities in China offered $5,115 in compensation to the parents of an infant who died after being given a vaccine made by Wosen Biotechnology. The company has begun its own investigation in the Shandong Province where a hospitalized child was injected with Wosen's vaccine against influenza B. The company and the family are divided on the need for an autopsy to learn the precise cause of death. Wosen said it sold more than 40,000 vaccines in China from the same batch linked with the death and does not know of any other side effects. The family is expected to sue Wosen if local authorities find quality issues with the firm's production process. (Click here for more

You may also be interested in...



Vous Has Advisors To Guide Growth In Promising Personalized Vitamin Space

Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.

Targeting Exciting Inflammasome Field, NodThera Raises $55m

UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.

Mylan And Pfizer Announce Key Date For Viatris Merger

Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel